#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that many patients self-report using cannabis for anxiety, depression, and other mental health conditions despite the lack of rigorous evidence supporting efficacy, which creates a gap between patient expectations and clinical evidence. This knowledge helps providers have informed conversations about unproven treatments, discuss potential harms, and guide patients toward evidence-based mental health interventions. Without clear guidance on cannabis for psychiatric use, clinicians should document patient cannabis use carefully and monitor for adverse effects while advocating for higher-quality research to inform future clinical recommendations.
A growing number of patients report using cannabis to manage mental health conditions, but current clinical evidence does not support routine use for psychiatric disorders. This gap between patient perception and scientific evidence creates a clinical challenge for physicians who may encounter patients self-treating anxiety, depression, or other mental health conditions with cannabis. The absence of robust randomized controlled trials demonstrating efficacy for psychiatric indications means clinicians lack the evidence base needed to recommend cannabis as a standard treatment or to confidently advise patients about its safety and effectiveness in this context. This evidence gap is particularly concerning given that cannabis use may worsen certain psychiatric symptoms in vulnerable populations, including those with psychosis or bipolar disorder. Until higher-quality clinical research establishes clear benefits and safety profiles for specific mental health conditions, physicians should counsel patients against routine cannabis use for psychiatric symptoms and consider conventional, evidence-based treatments as first-line options. Clinicians encountering patients who use or are considering cannabis for mental health should acknowledge their concerns while explaining the current lack of evidence and discussing proven alternatives.
“What I tell patients in my practice is straightforward: self-reported symptom relief doesn’t equal clinical evidence, and the brain is too complex for us to recommend cannabis as a first-line treatment for anxiety or depression when we have medications with decades of safety data behind them. That said, for a narrow subset of patients who’ve failed conventional therapies or have specific conditions like chemotherapy-induced nausea, the risk-benefit calculation shifts, which is exactly why we need rigorous clinical trials instead of waiting for anecdotal reports to guide our prescribing.”
? While patient-reported use of cannabis for mental health conditions is increasingly common, the evidence base supporting its efficacy remains limited and inconsistent. Most clinical trials examining cannabis for anxiety, depression, and other psychiatric conditions have methodological limitations, small sample sizes, or show minimal benefit beyond placebo, and some evidence suggests potential harms including increased psychosis risk in vulnerable populations. Clinicians should recognize that patient beliefs about cannabis’s mental health benefits may be driven by subjective symptom relief, placebo effects, media messaging, or comparison to side effects of conventional medications rather than robust clinical evidence. Given these gaps, practitioners should screen patients using cannabis for mental health symptoms, discuss the lack of established safety and efficacy data, and continue to recommend evidence-based treatments such as psychotherapy and FDA-approved medications as first-line interventions while further research clarifies cannabis’s role in psychiatric care.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
